Shimbo I, Yamaguchi T, Odaka T, Nakajima K, Koide A, Koyama H, Saisho H. World J Gastroenterol. 2005 Dec 21;11(47):7520-4.
Synopsis: This study investigated the effect of Clostridium butyricum MIYAIRI 588 (CBM) on the fecal microbiota during antibiotic treatment of Helicobacter pylori (H. pylori). Thirty-five patients with gastric or duodenal ulcers positive for H. pylori were randomized either to 1-week amoxicillin, clarithromycin, lansoprazole (Group 1) or to the same regimen supplemented with CBM 7 d ahead of the triple therapy (Group 2). Stool samples were collected before and 2, 4, 7, 15, and 22 d after the starting eradication therapy, and intestinal microbiota examined. Obligate anaerobes decreased significantly on d 2, 4, 8 and 15 in Group 1. In contrast, anaerobes did not decrease significantly in Group 2. Escherichia coli was the dominant bacterium in Enterobacteriaceae before treatment, but was replaced by other species such as Klebsiella and Enterobacter after eradication in Group 1. This change was suppressed in Group 2. In addition, abdominal symptoms were less frequent in Group 2 than in Group 1. The use of CBM reduced the changes in the intestinal microbiota and decreased the incidence of gastrointestinal side effects during antibiotic triple therapy for H. pylori.